F. Hoffmann-La Roche Ltd: New data show Roche's subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly

Related Keywords

Japan ,United States ,Germany ,Switzerland ,China ,American ,America ,Gerard Tobin ,Nathalie Altermatt ,Levi Garraway ,Sileia Urech ,Loren Kalm ,Bruno Eschli ,Sabine Borngr ,Birgit Masjost ,Karsten Kleine ,Head Of Global Product Development ,Genentech ,Roche Group Media Relations ,China National Medical Products Administration ,American Society ,Roche Group ,American Society Of Hematology ,Chugai Pharmaceutical Co Ltd ,European Hematology Association ,Hybrid Congress ,Chief Medical Officer ,Global Product ,Annual Meeting ,Drug Evaluation Breakthrough Therapy Designation ,Priority Review ,National Medical Products ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Multicentre Study ,Paroxysmal Nocturnal ,Managed Care ,Specialty Pharmacy ,Sci Rep ,Optimized Crovalimab Dose ,Regimen Reduced ,Drug Target Complexes ,Paroxysmal Nocturnal Hemoglobinuria From ,